\-\ Texto\\:\\ \ \(0\)\
\-\ giant\\ cell\\ tumor\\ of\\ bone\ \(1\)\
\-\ 20\\-year\\ old\\ male\\ with\\ 6\\ month\\ history\\ of\\ progressively\\ worse\\ left\\ lower\\ leg\\ pain\\.\\ pain\\ worse\\ with\\ motion\\.\\ no\\ overlying\\ skin\\ changes\\ or\\ other\\ complaints\\.\\ full\\ range\\ of\\ motion\\ in\\ lower\\ extremity\\.\ \(0\)\
\-\ giant\\ cell\\ tumor\\ of\\ bone\\ \\(osteoclastoma\\)\\ is\\ usually\\ seen\\ in\\ patients\\ over\\ 20\\ years\\ of\\ age\\.\\ it\\ is\\ more\\ common\\ in\\ women\\ than\\ men\\.\\ the\\ classic\\ location\\ is\\ the\\ epiphysis\\ of\\ a\\ long\\ bone\\.\\ the\\ most\\ commonly\\ affected\\ sites\\ \\(in\\ order\\)\\ are\\ the\\ lower\\ end\\ of\\ the\\ femur\\,\\ upper\\ end\\ of\\ the\\ tibia\\,\\ and\\ lower\\ end\\ of\\ the\\ radius\\.\ \(0\)\
\-\ radiographically\\,\\ the\\ typical\\ appearance\\ of\\ a\\ giant\\ cell\\ tumor\\ is\\ that\\ of\\ an\\ entirely\\ lytic\\,\\ expansile\\ lesion\\ in\\ the\\ epiphysis\\,\\ usually\\ without\\ peripheral\\ bone\\ sclerosis\\ or\\ periosteal\\ reaction\\.\\ \ \(0\)\
\-\ microscopically\\,\\ the\\ two\\ main\\ components\\ are\\ the\\ so\\-called\\ stromal\\ cells\\ and\\ giant\\ cells\\.\\ in\\ addition\\,\\ focal\\ deposition\\ of\\ osteoid\\ or\\ bone\\ is\\ seen\\ in\\ one\\ third\\ of\\ cases\\.\\ the\\ giant\\ cells\\ are\\ usually\\ large\\ and\\ may\\ contain\\ 20\\-30\\ nuclei\\.\\ it\\ is\\ the\\ relative\\ number\\ and\\ appearance\\ of\\ the\\ stromal\\ cells\\,\\ not\\ those\\ of\\ the\\ giant\\ cells\\,\\ that\\ correlate\\ with\\ the\\ clinical\\ evolution\\ of\\ the\\ tumor\\.\\ in\\ most\\ reported\\ series\\,\\ the\\ incidence\\ of\\ clinical\\ malignancy\\ in\\ giant\\ cell\\ tumors\\ is\\ in\\ the\\ range\\ of\\ 10\\%\\.\\ radiation\\ therapy\\ should\\ be\\ reserved\\ only\\ for\\ cases\\ in\\ which\\ surgical\\ removal\\ is\\ impossible\\,\\ in\\ view\\ of\\ the\\ relatively\\ high\\ number\\ of\\ reported\\ cases\\ of\\ malignant\\ transformation\\ following\\ therapeutic\\ modality\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ giant\\:\\ 0\\.4100081155937859\ \(0\)\
\-\ of\\:\\ 0\\.2698553378376081\ \(0\)\
\-\ the\\:\\ 0\\.26204898603665105\ \(0\)\
\-\ cells\\:\\ 0\\.25296789450857626\ \(0\)\
\-\ in\\:\\ 0\\.19602239142020345\ \(0\)\
\-\ bone\\:\\ 0\\.1791430195116251\ \(0\)\
\-\ end\\:\\ 0\\.17335555566220587\ \(0\)\
\-\ cell\\:\\ 0\\.150252502761966\ \(0\)\
\-\ is\\:\\ 0\\.14386137997991066\ \(0\)\
\-\ stromal\\:\\ 0\\.14347995843057446\ \(0\)\
\-\ tumor\\:\\ 0\\.13738539656694576\ \(0\)\
\-\ lower\\:\\ 0\\.1342185477018282\ \(0\)\
\-\ cases\\:\\ 0\\.13249874610545948\ \(0\)\
\-\ epiphysis\\:\\ 0\\.12987666063068343\ \(0\)\
\-\ 20\\:\\ 0\\.12708801574713485\ \(0\)\
\-\ usually\\:\\ 0\\.12401472799951327\ \(0\)\
\-\ number\\:\\ 0\\.12089876443248539\ \(0\)\
\-\ worse\\:\\ 0\\.11001820407485913\ \(0\)\
\-\ range\\:\\ 0\\.10191152260924523\ \(0\)\
\-\ motion\\:\\ 0\\.1018066360790973\ \(0\)\
\-\ osteoclastoma\\:\\ 0\\.10034442741751348\ \(0\)\
\-\ microscopically\\:\\ 0\\.0970328394587231\ \(0\)\
\-\ reported\\:\\ 0\\.09458946340870247\ \(0\)\
\-\ impossible\\:\\ 0\\.0905909472369318\ \(0\)\
\-\ clinical\\:\\ 0\\.08323016059937245\ \(0\)\
\-\ appearance\\:\\ 0\\.0791731774648118\ \(0\)\
\-\ evolution\\:\\ 0\\.07689731579770274\ \(0\)\
\-\ reserved\\:\\ 0\\.076407400296751\ \(0\)\
\-\ are\\:\\ 0\\.07475008670632066\ \(0\)\
\-\ osteoid\\:\\ 0\\.07239794553693786\ \(0\)\
\-\ nuclei\\:\\ 0\\.07239794553693786\ \(0\)\
\-\ correlate\\:\\ 0\\.07239794553693786\ \(0\)\
\-\ entirely\\:\\ 0\\.07142458204009558\ \(0\)\
\-\ or\\:\\ 0\\.06853054252213282\ \(0\)\
\-\ most\\:\\ 0\\.06834760001295917\ \(0\)\
\-\ it\\:\\ 0\\.06722549092529809\ \(0\)\
\-\ transformation\\:\\ 0\\.06707255813382344\ \(0\)\
\-\ men\\:\\ 0\\.06686133612005697\ \(0\)\
\-\ therapeutic\\:\\ 0\\.06645017538540275\ \(0\)\
\-\ deposition\\:\\ 0\\.06624997422147147\ \(0\)\
\-\ contain\\:\\ 0\\.06566945070744427\ \(0\)\
\-\ radius\\:\\ 0\\.0654822713512066\ \(0\)\
\-\ radiographically\\:\\ 0\\.0654822713512066\ \(0\)\
\-\ modality\\:\\ 0\\.06493833031534171\ \(0\)\
\-\ progressively\\:\\ 0\\.06425088567598479\ \(0\)\
\-\ sites\\:\\ 0\\.06408525293675126\ \(0\)\
\-\ seen\\:\\ 0\\.0618286403325299\ \(0\)\
\-\ order\\:\\ 0\\.06069173383654643\ \(0\)\
\-\ series\\:\\ 0\\.060212027894378004\ \(0\)\
\-\ components\\:\\ 0\\.05963920938517233\ \(0\)\
\-\ expansile\\:\\ 0\\.05941783185528746\ \(0\)\
\-\ women\\:\\ 0\\.05909354909356928\ \(0\)\
\-\ relative\\:\\ 0\\.05817215533183222\ \(0\)\
\-\ periosteal\\:\\ 0\\.05778518522073528\ \(0\)\
\-\ main\\:\\ 0\\.0572280792439905\ \(0\)\
\-\ that\\:\\ 0\\.056991870616104265\ \(0\)\
\-\ incidence\\:\\ 0\\.05652488191415122\ \(0\)\
\-\ those\\:\\ 0\\.056188762362933915\ \(0\)\
\-\ tibia\\:\\ 0\\.05610624389649709\ \(0\)\
\-\ overlying\\:\\ 0\\.05594296063717244\ \(0\)\
\-\ reaction\\:\\ 0\\.05586217941602002\ \(0\)\
\-\ lytic\\:\\ 0\\.05531204785740656\ \(0\)\
\-\ and\\:\\ 0\\.05427506918755438\ \(0\)\
\-\ complaints\\:\\ 0\\.054076214239017525\ \(0\)\
\-\ affected\\:\\ 0\\.05400748999445137\ \(0\)\
\-\ femur\\:\\ 0\\.05387126027701148\ \(0\)\
\-\ relatively\\:\\ 0\\.05347198521896672\ \(0\)\
\-\ addition\\:\\ 0\\.05314951940568156\ \(0\)\
\-\ full\\:\\ 0\\.051329710369906634\ \(0\)\
\-\ typical\\:\\ 0\\.05074740671564954\ \(0\)\
\-\ removal\\:\\ 0\\.050193146291578054\ \(0\)\
\-\ third\\:\\ 0\\.04999803523463823\ \(0\)\
\-\ leg\\:\\ 0\\.04957076354315736\ \(0\)\
\-\ malignancy\\:\\ 0\\.04915878521719816\ \(0\)\
\-\ classic\\:\\ 0\\.04911390688833285\ \(0\)\
\-\ skin\\:\\ 0\\.048848250249797324\ \(0\)\
\-\ commonly\\:\\ 0\\.04858858638032094\ \(0\)\
\-\ tumors\\:\\ 0\\.04829286759547647\ \(0\)\
\-\ view\\:\\ 0\\.04808619639290728\ \(0\)\
\-\ extremity\\:\\ 0\\.04729473170435124\ \(0\)\
\-\ pain\\:\\ 0\\.046994357243526005\ \(0\)\
\-\ peripheral\\:\\ 0\\.04695558609128021\ \(0\)\
\-\ malignant\\:\\ 0\\.04680800359834541\ \(0\)\
\-\ sclerosis\\:\\ 0\\.046771401733569515\ \(0\)\
\-\ location\\:\\ 0\\.04572420041605841\ \(0\)\
\-\ long\\:\\ 0\\.043542332241215974\ \(0\)\
\-\ radiation\\:\\ 0\\.04351476030761845\ \(0\)\
\-\ should\\:\\ 0\\.04284608937710407\ \(0\)\
\-\ age\\:\\ 0\\.04122483015529353\ \(0\)\
\-\ only\\:\\ 0\\.0410234615782713\ \(0\)\
\-\ years\\:\\ 0\\.04025146665845126\ \(0\)\
\-\ month\\:\\ 0\\.0399444810852222\ \(0\)\
\-\ changes\\:\\ 0\\.039684892291166875\ \(0\)\
\-\ following\\:\\ 0\\.03939246479348525\ \(0\)\
\-\ focal\\:\\ 0\\.03927754260662976\ \(0\)\
\-\ two\\:\\ 0\\.03899515861563157\ \(0\)\
\-\ with\\:\\ 0\\.03857379661966616\ \(0\)\
\-\ 10\\:\\ 0\\.03839727108174308\ \(0\)\
\-\ therapy\\:\\ 0\\.03772852044345737\ \(0\)\
\-\ one\\:\\ 0\\.03759601507507548\ \(0\)\
\-\ high\\:\\ 0\\.0373194057163349\ \(0\)\
\-\ common\\:\\ 0\\.0372392990828727\ \(0\)\
\-\ than\\:\\ 0\\.03722334443475579\ \(0\)\
\-\ patients\\:\\ 0\\.03693987869966089\ \(0\)\
\-\ over\\:\\ 0\\.03651235509548021\ \(0\)\
\-\ more\\:\\ 0\\.036056839914761184\ \(0\)\
\-\ upper\\:\\ 0\\.035090097802498124\ \(0\)\
\-\ without\\:\\ 0\\.03463556082120693\ \(0\)\
\-\ other\\:\\ 0\\.0341006348654219\ \(0\)\
\-\ may\\:\\ 0\\.03304445253801714\ \(0\)\
\-\ large\\:\\ 0\\.03290117965159161\ \(0\)\
\-\ surgical\\:\\ 0\\.03191509438568488\ \(0\)\
\-\ lesion\\:\\ 0\\.03148102738324615\ \(0\)\
\-\ which\\:\\ 0\\.029858306540959733\ \(0\)\
\-\ male\\:\\ 0\\.02923636635522623\ \(0\)\
\-\ be\\:\\ 0\\.02663746704028907\ \(0\)\
\-\ not\\:\\ 0\\.025922786998321113\ \(0\)\
\-\ an\\:\\ 0\\.025109888637044202\ \(0\)\
\-\ history\\:\\ 0\\.025087644617033472\ \(0\)\
\-\ left\\:\\ 0\\.022399596888919703\ \(0\)\
\-\ no\\:\\ 0\\.021353351840195833\ \(0\)\
\-\ for\\:\\ 0\\.01990240936872061\ \(0\)\
\-\ old\\:\\ 0\\.019434054167191024\ \(0\)\
